233 related articles for article (PubMed ID: 37207222)
1. Integrating machine learning and single-cell trajectories to analyze T-cell exhaustion to predict prognosis and immunotherapy in colon cancer patients.
Shen X; Zuo X; Liang L; Wang L; Luo B
Front Immunol; 2023; 14():1162843. PubMed ID: 37207222
[TBL] [Abstract][Full Text] [Related]
2. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
[No Abstract] [Full Text] [Related]
3. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.
Nan H; Guo P; Fan J; Zeng W; Hu C; Zheng C; Pan B; Cao Y; Ge Y; Xue X; Li W; Lin K
Front Immunol; 2023; 14():1093974. PubMed ID: 36949947
[TBL] [Abstract][Full Text] [Related]
5. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
6. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
[TBL] [Abstract][Full Text] [Related]
7. Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms.
Liang W; Yang X; Li X; Wang P; Zhu Z; Liu S; Xu D; Zhi X; Xue J
Aging (Albany NY); 2024 May; 16(9):7596-7621. PubMed ID: 38742936
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.
Chi H; Huang J; Yan Y; Jiang C; Zhang S; Chen H; Jiang L; Zhang J; Zhang Q; Yang G; Tian G
Front Mol Biosci; 2023; 10():1254232. PubMed ID: 37916187
[No Abstract] [Full Text] [Related]
9. A pairwise immune gene model for predicting overall survival and stratifying subtypes of colon adenocarcinoma.
Jiang Z; Xu J; Zhang S; Lan H; Bao Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10813-10829. PubMed ID: 37316691
[TBL] [Abstract][Full Text] [Related]
10. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
[No Abstract] [Full Text] [Related]
11. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
Front Immunol; 2022; 13():881359. PubMed ID: 35911752
[TBL] [Abstract][Full Text] [Related]
12. Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response.
Li C; Zhang K; Gong Y; Wu Q; Zhang Y; Dong Y; Li D; Wang Z
Front Pharmacol; 2023; 14():1200054. PubMed ID: 37377924
[No Abstract] [Full Text] [Related]
13. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
[No Abstract] [Full Text] [Related]
14. High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity.
Huang X; Cao Y; Bao P; Zhu B; Cheng Z
Cancer Med; 2023 Jan; 12(1):837-851. PubMed ID: 35634680
[TBL] [Abstract][Full Text] [Related]
15. Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma.
Zou Z; Chai Y; Li Q; Lin X; He Q; Xiong Q
Front Oncol; 2022; 12():958221. PubMed ID: 36185199
[TBL] [Abstract][Full Text] [Related]
16. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
Lin A; Gu T; Hu X; Zhang J; Luo P
J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Characterization of RNA-Binding Proteins in Colon Adenocarcinoma Identifies a Novel Prognostic Signature for Predicting Clinical Outcomes and Immunotherapy Responses Based on Machine Learning.
Miao Y; Yuan Q; Wang C; Feng X; Ren J; Wang C
Comb Chem High Throughput Screen; 2023; 26(1):163-182. PubMed ID: 35379120
[TBL] [Abstract][Full Text] [Related]
19. A Novel Pyroptosis-Related Gene Signature for Predicting the Prognosis and the Associated Immune Infiltration in Colon Adenocarcinoma.
Chen Z; Han Z; Nan H; Fan J; Zhan J; Zhang Y; Zhu H; Cao Y; Shen X; Xue X; Lin K
Front Oncol; 2022; 12():904464. PubMed ID: 35912258
[TBL] [Abstract][Full Text] [Related]
20. A Prognostic Model for Colon Adenocarcinoma Patients Based on Ten Amino Acid Metabolism Related Genes.
Ren Y; He S; Feng S; Yang W
Front Public Health; 2022; 10():916364. PubMed ID: 35712285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
